Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

The Pharmacogenomics "Side-Effect" of TP53/EGFR in Non-Small Cell Lung Cancer Companied with Atorvastatin Therapy: A Functional Network Analysis.

Zhang L, Huang Y, Gan X, He S, Cheng X, Yang N, Li S, Li Z, Zheng F.

Anticancer Agents Med Chem. 2019 Jul 12. doi: 10.2174/1871520619666190712203217. [Epub ahead of print]

PMID:
31544704
2.

Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia.

Zhang L, He S, Li Z, Gan X, Li S, Cheng X, Yang N, Zheng F.

Lipids Health Dis. 2019 Jun 1;18(1):129. doi: 10.1186/s12944-019-1069-5.

3.

Deletion of Pr72 causes cardiac developmental defects in Zebrafish.

Song G, Han M, Li Z, Gan X, Chen X, Yang J, Dong S, Yan M, Wan J, Wang Y, Huang Z, Yin Z, Zheng F.

PLoS One. 2018 Nov 27;13(11):e0206883. doi: 10.1371/journal.pone.0206883. eCollection 2018.

4.

Occurrence of composite cardiac endpoints with change in resting heart rate among Chinese patients with coronary artery disease: Chinese cohort from the real-world BISO-CAD study.

Chen Y, Yang X, Huang S, Fu G, Chen X, Yang Y, Liu S, Xu H, Ma T, Zhou X, Lv Z, Yang M, Gan X, Xu D, Cao F, Liu H, Li J, Zheng Q, Wang N, Yuan Y, Liu W, Yang T.

Curr Med Res Opin. 2018 Nov;34(11):1921-1926. doi: 10.1080/03007995.2018.1454895. Epub 2018 Apr 25.

PMID:
29557206
5.

Chocolate Consumption and Risk of Heart Failure: A Meta-Analysis of Prospective Studies.

Gong F, Yao S, Wan J, Gan X.

Nutrients. 2017 Apr 20;9(4). pii: E402. doi: 10.3390/nu9040402.

6.

Deletion of Pr130 Interrupts Cardiac Development in Zebrafish.

Yang J, Li Z, Gan X, Zhai G, Gao J, Xiong C, Qiu X, Wang X, Yin Z, Zheng F.

Int J Mol Sci. 2016 Nov 11;17(11). pii: E1746.

7.

Pioglitazone modulates the proliferation and apoptosis of vascular smooth muscle cells via peroxisome proliferators-activated receptor-gamma.

Wan J, Xiao Z, Chao S, Xiong S, Gan X, Qiu X, Xu C, Ma Y, Tu X.

Diabetol Metab Syndr. 2014 Sep 19;6(1):101. doi: 10.1186/1758-5996-6-101. eCollection 2014.

8.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators.

JAMA. 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321.

PMID:
24682069
9.

High plasma fatty acid concentrations were present in non-diabetic patients with coronary heart disease.

Yang N, Guo S, Zheng F, Gan X, Ning L, Dong S.

Clin Lab. 2014;60(1):125-31.

PMID:
24600986
10.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators.

N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.

Supplemental Content

Loading ...
Support Center